KORU Medical Systems, Inc. (KRMD)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
$3.03-7.34%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
QuarterlyIQ Insights · KRMD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -59.7% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 21.2% |
Growth built into the price is above our model estimate.
The price assumes 80.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 15 industry peers
KRMD — earnings in line
Dated 2026-05-06
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. (a) Public Announcement or Release . On May 6, 2026, KORU Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the first fiscal quarter ended March 31, 2026 and reiterating financial guidance for the fiscal year ended December 31, 2026. The Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. A related conference call will be held on May 6, 2026 at 4:30pm Eastern Tim…
Why it matters: That would meet the low end of the latest full-year revenue range. It would show growth stayed on track despite slower international sales.
Supportive ifFull-year 2026 revenue is at least $47.5 million, the low end of guidance.
Worry ifFull-year revenue is below $47.5 million, or management cuts the range below that level.
Why it matters: Cash was $8.3 million at June 30, and the company lowered its year-end cash goal after buying a technology asset. Falling below the new floor would weaken that plan.
Worry ifThe year-end 2026 cash balance is above $7.5 million, as guided.
Less concerning ifThe year-end cash balance is $7.5 million or less, or management lowers its cash goal again.
Why it matters: International core sales grew 59.1% in Q2. Distributor orders for pre-filled syringes helped. Management said growth may slow as some markets switch products.
Worry ifInternational core revenue falls year over year in a later 2026 quarter. Or management reports weaker orders tied to PFS conversions.
Less concerning ifInternational core revenue grows year over year in the next report, with no new delay in PFS market orders.
Why it matters: Second-quarter margin reached 65.1%, above the new range. Staying near or above 62% would support the margin gains seen this year.
Supportive ifA later 2026 report shows gross margin at or above 62%, without a cut to the 62% to 64% range.
Worry ifA later 2026 report shows gross margin below 62%, or management lowers the range.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$146 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $444 loss on $10,000 · 4.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,506 loss on $10,000 · 55.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: KORU ended this U.S. product path and shifted its oncology focus to other drugs with higher infusion volumes. A named next step would show the new plan is moving.
Watch forKORU names an oncology drug with higher volume. It also reports a specific step for the Freedom System with regulators or in sales.
Also watch forKORU reports no named alternative drug or next step in its next two company updates.